Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 17, 2026. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). These documents are available on the company’s website:https://www.sanofi.com/en/investors/reports-an ...

Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Paris and Pa ...

Core Insights - A universal RSV immunization program using Beyfortus (nirsevimab) significantly reduced RSV-related hospitalizations in infants during their second RSV season after immunization in their first season [1][3] Group 1: Study Findings - The NIRSE-GAL study in Galicia, Spain, demonstrated a 94.4% coverage rate with 11,796 out of 12,492 eligible infants immunized [2] - There was an 85.9% reduction in RSV-related lower respiratory tract infection (LRTI) hospitalizations during the first season [2][6] - Infants who received Beyfortus during infancy experienced a 55.3% reduction in hospitalizations during their second RSV season [2] - The study also reported a 78.2% reduction in RSV-related rehospitalizations and a 62.4% reduction in LRTI rehospitalizations during the second season [4] Group 2: Implications for Public Health - The findings support the hypothesis that early protection against RSV-related lung damage may have lasting benefits on respiratory health [4] - The results provide compelling data to inform infant immunization strategies and economic evaluation models [3] Group 3: About Beyfortus - Beyfortus is designed to protect all infants during their first RSV season, including those born healthy at term or preterm, and those with health conditions [9] - It is a long-acting monoclonal antibody with an extended half-life of 71 days, administered as a single dose [10] - Over 11 million infants have been immunized with Beyfortus across more than 45 countries since its launch [11]

Group 1 - Banco Santander, S.A. is considered one of the best undervalued European stocks to buy currently, despite Morgan Stanley reducing its rating to Equalweight from Overweight due to limited upside and increased execution risk related to its growth in the U.S. following the acquisition of Webster Financial [1][3] - Morgan Stanley forecasts that the Webster acquisition will yield a return on investment of 13% to 14%, which is below Santander's expectations, and anticipates a 5% to 6% increase in earnings by 2028 [3][4] - The estimates for the Webster acquisition are viewed as ambitious, as they assume cost synergies exceeding €800 million, approximately 55% of Webster's cost base [4] Group 2 - Banco Santander announced a €5 billion share repurchase, which aligns with Morgan Stanley's projections and includes a significant buyback related to the sale of its Polish operations [5] - Banco Santander is a major retail and commercial bank based in Spain, with a strong market presence in key European and American markets, focusing on consumer and business lending, deposit-taking, and payment services [6]

经济观察网 桑坦德银行（股票代码：SAN）近期有多项关键事件可能影响其市场表现。 近期事件 资金动向 董事会已批准新一轮50亿欧元的股票回购计划，并重申在2025至2026年间实现总额不低于100亿欧元的 股东分配目标（包括回购与分红）。这一资本运作方案可能对股价流动性及投资者情绪产生影响。 业绩经营情况 在2025财年，银行净利润创纪录达141.01亿欧元（同比增长12%），核心一级资本充足率（CET1）升至 13.5%的历史高位。市场可能持续关注其资产质量（如不良贷款率已优化至2.91%）及后续季度业绩的 可持续性。 以上内容基于公开资料整理，不构成投资建议。 桑坦德银行定于2026年2月25日举行投资者日，届时将公布新的财务目标及长期战略规划。该事件是银 行向市场传递未来增长路径的重要节点，可能引发市场对业务前景的重新评估。 公司项目推进 银行于2026年2月4日宣布计划以120亿美元收购美国韦伯斯特金融公司（WBS），交易预计在2026年下 半年完成法定交割程序。若成功，将催生总资产达3270亿美元的新实体，直接跻身美国银行业前十强。 这一扩张计划是欧洲银行在美最大交易之一，旨在提升美国业务的有形股本 ...

Core Viewpoint - Sanofi's Board of Directors has appointed Belén Garijo as the new Chief Executive Officer, effective after the Annual General Meeting on April 29, 2026, following the decision not to renew Paul Hudson's mandate [1][2][6]. Group 1: Leadership Transition - Paul Hudson's tenure as CEO will conclude on February 17, 2026, after six years of contributions to the company's transformation [1]. - Olivier Charmeil will serve as Interim Chief Executive Officer during the transition period until Garijo officially takes over [3]. Group 2: Belén Garijo's Background - Belén Garijo has a notable career in the pharmaceutical industry, having joined Merck KGaA in 2011 and becoming its CEO in 2021, marking her as the first woman to lead a DAX40 company in Germany [4]. - She has extensive experience at Sanofi, where she held significant roles for 15 years, including Vice President of Pharmaceutical Operations for Europe and Canada [4][6]. Group 3: Strategic Focus - Garijo's leadership is expected to enhance the implementation of Sanofi's strategy, focusing on productivity, governance, and innovation in Research & Development [3][6]. - The Board of Directors expressed confidence in Garijo's ability to drive growth and execute strategic initiatives effectively, emphasizing her international experience and reputation in the industry [6].

Core Viewpoint - The document provides information regarding the total number of voting rights and shares of Sanofi, a French société anonyme, as required by French commercial regulations. Group 1: Company Information - Sanofi has a registered share capital of €2,438,854,192 [1] - The company is registered at the Paris Commercial and Companies Registry under number 395 030 844 [1] Group 2: Voting Rights and Shares - As of January 31, 2026, Sanofi has issued a total of 1,219,502,262 shares [1] - The number of real voting rights, excluding treasury shares, is 1,341,656,083 [1] - The theoretical number of voting rights, including treasury shares, is 1,353,618,860 [1]

Core Insights - Sanofi has completed the acquisition of Dynavax Technologies Corporation, enhancing its portfolio in adult immunization with Dynavax's hepatitis B vaccine HEPLISAV-B and shingles vaccine candidate Z-1018 [1][2] Acquisition Details - The tender offer for Dynavax's common stock expired on February 9, 2026, and all conditions were satisfied, leading to Sanofi's acceptance of the shares [3] - The acquisition was finalized through a merger, with Dynavax becoming a wholly owned subsidiary of Sanofi, and shares not tendered in the offer will receive $15.50 per share in cash [4] Strategic Implications - This acquisition strengthens Sanofi's commercial reach and development capabilities in the vaccine market, positioning the company for growth in adult immunization [2]

Renewable energy company Zelestra has agreed a €130m ($154m) syndicated equity-bond facility with Santander, with backing from Instituto de Credito Oficial (ICO) and Spain's official export credit agency, CESCE. This financial arrangement is intended to support the development of approximately 500MW of contracted renewable energy projects in Germany, Italy and the US. These projects, which include wind, solar and battery energy storage capacities, are expected to begin construction in 2026 and 2027. Th ...

Institutional Presentation FY'25 Strategic and Financial Analysis. Financial Division INDEX Our business model and strategy Group structure and businesses FY'25 results & activity Final remarks Links to public materials Logotipo El contenido generado por IA puede ser incorrecto. Our business model and strategy Santander, a leading financial group | FY'25 Highlights | | | | --- | --- | --- | | Total assets (€ bn) | 1 , | 868 | | Customer loans bn (€ excluding reverse repos) | 1 , | 024 | | Customer deposits ...